BACKGROUND:TIMI (Thrombolysisin Myocardial Infarction) Risk Index (TRI) is a simple bedside score that predicts 30-day mortality in patients with ST-elevation myocardial infarction (MI). We sought to evaluate whether TRI was predictive of long-term mortality and clinical events. METHODS: In the TIMI 2 trial, 3,153 patients (mean age 57 +/- 10 years, 82% men) were randomized to invasive (n = 1,583) versus conservative (n = 1,570) strategy postfibrinolysis with median follow-up of 3 years. TIMI Risk Index was divided into 5 groups. The primary end point was all-cause mortality. Secondary analyses included recurrent MI, congestive heart failure (CHF), and combined end points. RESULTS: When compared with group 1, mortality in group 5 was more than 5-fold higher (hazard ratio [HR] 5.83, P < .0001) and was also increased in group 4 (HR 2.80, P < .0001) and group 3 (HR 1.96, P = .002) (c statistic 0.69). No difference was seen between groups 1 and 2 (P = .74). A similar increasing gradient effect was seen across TRI strata with group 5 having the highest risk for CHF (HR 4.13, P < .0001) and the highest risk for composite death/CHF (HR 4.35, P < .0001) over group 1. There was no difference in recurrent MI between the groups (P = .22). After controlling for other risk indicators, the relationship between TRI and mortality remained significant: group 5, HR 4.11, P < .0001; group 4, HR 2.14, P = .0009; group 3, HR 1.69, P = .02. When stratified by TRI groups, no differences in mortality or composite death/MI were found between treatment strategies. CONCLUSIONS: The simple TRI can predict increased long-term mortality, CHF, and composite death/CHF.
RCT Entities:
BACKGROUND: TIMI (Thrombolysis in Myocardial Infarction) Risk Index (TRI) is a simple bedside score that predicts 30-day mortality in patients with ST-elevation myocardial infarction (MI). We sought to evaluate whether TRI was predictive of long-term mortality and clinical events. METHODS: In the TIMI 2 trial, 3,153 patients (mean age 57 +/- 10 years, 82% men) were randomized to invasive (n = 1,583) versus conservative (n = 1,570) strategy postfibrinolysis with median follow-up of 3 years. TIMI Risk Index was divided into 5 groups. The primary end point was all-cause mortality. Secondary analyses included recurrent MI, congestive heart failure (CHF), and combined end points. RESULTS: When compared with group 1, mortality in group 5 was more than 5-fold higher (hazard ratio [HR] 5.83, P < .0001) and was also increased in group 4 (HR 2.80, P < .0001) and group 3 (HR 1.96, P = .002) (c statistic 0.69). No difference was seen between groups 1 and 2 (P = .74). A similar increasing gradient effect was seen across TRI strata with group 5 having the highest risk for CHF (HR 4.13, P < .0001) and the highest risk for composite death/CHF (HR 4.35, P < .0001) over group 1. There was no difference in recurrent MI between the groups (P = .22). After controlling for other risk indicators, the relationship between TRI and mortality remained significant: group 5, HR 4.11, P < .0001; group 4, HR 2.14, P = .0009; group 3, HR 1.69, P = .02. When stratified by TRI groups, no differences in mortality or composite death/MI were found between treatment strategies. CONCLUSIONS: The simple TRI can predict increased long-term mortality, CHF, and composite death/CHF.
Authors: Stephen D Wiviott; David A Morrow; Paul D Frederick; Elliott M Antman; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2006-03-29 Impact factor: 24.094
Authors: Benjamin M Scirica; David A Morrow; Christopher P Cannon; Kausik K Ray; Marc S Sabatine; Petr Jarolim; Amy Shui; Carolyn H McCabe; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2006-05-04 Impact factor: 24.094
Authors: D A Morrow; E M Antman; L Parsons; J A de Lemos; C P Cannon; R P Giugliano; C H McCabe; H V Barron; E Braunwald Journal: JAMA Date: 2001-09-19 Impact factor: 56.272
Authors: Leonard Ilkhanoff; Christopher J O'Donnell; Carlos A Camargo; T David O'Halloran; Robert P Giugliano; Donald M Lloyd-Jones Journal: Am J Cardiol Date: 2005-09-15 Impact factor: 2.778
Authors: Kiran K Khush; David D Waters; Vera Bittner; Prakash C Deedwania; John J P Kastelein; Sandra J Lewis; Nanette K Wenger Journal: Circulation Date: 2007-01-29 Impact factor: 29.690
Authors: Wei-Ching Chang; Padma Kaul; Yuling Fu; Cynthia M Westerhout; Christopher B Granger; Kenneth W Mahaffey; Lars Wallentin; Frans Van de Werf; Paul W Armstrong Journal: Eur Heart J Date: 2006-01-11 Impact factor: 29.983
Authors: Stephen D Wiviott; David A Morrow; Paul D Frederick; Robert P Giugliano; C Michael Gibson; Carolyn H McCabe; Christopher P Cannon; Elliott M Antman; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2004-08-18 Impact factor: 24.094
Authors: D O Williams; E Braunwald; G Knatterud; J Babb; J Bresnahan; M A Greenberg; A Raizner; A Wasserman; T Robertson; R Ross Journal: Circulation Date: 1992-02 Impact factor: 29.690
Authors: M L Terrin; D O Williams; N S Kleiman; J Willerson; H S Mueller; P Desvigne-Nickens; S A Forman; G L Knatterud; E Braunwald Journal: J Am Coll Cardiol Date: 1993-12 Impact factor: 24.094
Authors: Eric S Ketchum; Kenneth Dickstein; John Kjekshus; Bertram Pitt; Meagan F Wong; David T Linker; Wayne C Levy Journal: Eur Heart J Acute Cardiovasc Care Date: 2013-09-11
Authors: Jay S Shavadia; Wendimagegn Alemayehu; Christopher deFilippi; Cynthia M Westerhout; Jasper Tromp; Christopher B Granger; Paul W Armstrong; Sean van Diepen Journal: J Thromb Thrombolysis Date: 2021-10-27 Impact factor: 2.300